Literature DB >> 31037615

Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Sameed Ahmed1, Miandra Ellis2, Hongshan Li3, Luca Pallucchini4, Andrew M Stein5.   

Abstract

Guiding the dose selection for monoclonal antibody oncology drugs is often done using methods for predicting the receptor occupancy of the drug in the tumor. In this manuscript, previous work on characterizing target inhibition at steady state using the AFIR metric (Stein and Ramakrishna in CPT Pharmacomet Syst Pharmacol 6(4):258-266, 2017) is extended to include a "target-tissue" compartment and the shedding of membrane-bound targets. A new potency metric average free tissue target to initial target ratio (AFTIR) at steady state is derived, and it depends on only four key quantities: the equilibrium binding constant, the fold-change in target expression at steady state after binding to drug, the biodistribution of target from circulation to target tissue, and the average drug concentration in circulation. The AFTIR metric is useful for guiding dose selection, for efficiently performing sensitivity analyses, and for building intuition for more complex target mediated drug disposition models. In particular, reducing the complex, physiological model to four key parameters needed to predict target inhibition helps to highlight specific parameters that are the most important to estimate in future experiments to guide drug development.

Entities:  

Keywords:  Monoclonal antibody; Pharmacokinetics and pharmacodynamics; Pharmacometrics; Target mediated drug disposition

Year:  2019        PMID: 31037615     DOI: 10.1007/s10928-019-09638-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  27 in total

1.  Ligand-independent internalization and recycling of the insulin receptor. Effects of chronic treatment of 3T3-C2 fibroblasts with insulin and dexamethasone.

Authors:  V P Knutson
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

2.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

Authors:  Rong Deng; Daniela Bumbaca; Cinthia V Pastuskovas; C Andrew Boswell; David West; Kyra J Cowan; Henry Chiu; Jacqueline McBride; Clarissa Johnson; Yan Xin; Hartmut Koeppen; Maya Leabman; Suhasini Iyer
Journal:  MAbs       Date:  2016-02-26       Impact factor: 5.857

Review 3.  Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.

Authors:  Jean W Lee; Marian Kelley; Lindsay E King; Jihong Yang; Hossein Salimi-Moosavi; Meina T Tang; Jian-Feng Lu; John Kamerud; Ago Ahene; Heather Myler; Cindy Rogers
Journal:  AAPS J       Date:  2011-01-15       Impact factor: 4.009

4.  Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.

Authors:  Abhinav Tiwari; Anson K Abraham; John M Harrold; Anup Zutshi; Pratap Singh
Journal:  AAPS J       Date:  2016-12-21       Impact factor: 4.009

5.  A mechanistic compartmental model for total antibody uptake in tumors.

Authors:  Greg M Thurber; K Dane Wittrup
Journal:  J Theor Biol       Date:  2012-09-06       Impact factor: 2.691

Review 6.  In vivo microdialysis for PK and PD studies of anticancer drugs.

Authors:  Qingyu Zhou; James M Gallo
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

7.  Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  MAbs       Date:  2013-02-13       Impact factor: 5.857

8.  Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis.

Authors:  Ben-Fillippo Krippendorff; Katharina Kuester; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

Review 9.  Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development.

Authors:  Meina Liang; Martin Schwickart; Amy K Schneider; Inna Vainshtein; Christopher Del Nagro; Nathan Standifer; Lorin K Roskos
Journal:  Cytometry B Clin Cytom       Date:  2015-07-31       Impact factor: 3.058

10.  AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.

Authors:  A M Stein; R Ramakrishna
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-04
View more
  5 in total

1.  An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.

Authors:  Bruna Menezes; Cornelius Cilliers; Timothy Wessler; Greg M Thurber; Jennifer J Linderman
Journal:  AAPS J       Date:  2020-01-15       Impact factor: 4.009

Review 2.  Which factors matter the most? Revisiting and dissecting antibody therapeutic doses.

Authors:  Yu Tang; Xiaobing Li; Yanguang Cao
Journal:  Drug Discov Today       Date:  2021-04-22       Impact factor: 8.369

Review 3.  Beyond Deterministic Models in Drug Discovery and Development.

Authors:  Itziar Irurzun-Arana; Christopher Rackauckas; Thomas O McDonald; Iñaki F Trocóniz
Journal:  Trends Pharmacol Sci       Date:  2020-10-05       Impact factor: 14.819

4.  Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Authors:  Patrick Schöffski; Daniel S W Tan; Miguel Martín; María Ochoa-de-Olza; John Sarantopoulos; Richard D Carvajal; Chrisann Kyi; Taito Esaki; Amy Prawira; Wallace Akerley; Filippo De Braud; Rina Hui; Tian Zhang; Ross A Soo; Michela Maur; Andrew Weickhardt; Jürgen Krauss; Barbara Deschler-Baier; Allen Lau; Tanay S Samant; Tyler Longmire; Niladri Roy Chowdhury; Catherine A Sabatos-Peyton; Nidhi Patel; Radha Ramesh; Tiancen Hu; Ana Carion; Daniel Gusenleitner; Padmaja Yerramilli-Rao; Vasileios Askoxylakis; Eunice L Kwak; David S Hong
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

Review 5.  Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.

Authors:  Yu Tang; Yanguang Cao
Journal:  Pharmaceutics       Date:  2021-03-21       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.